Lantern Pharma Inc. (LTRN)
3.61
0.16 (4.64%)
At close: Apr 23, 2025, 3:45 PM
4.64% (1D)
| Bid | 3.3 |
| Market Cap | 38.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.78M |
| EPS (ttm) | -1.93 |
| PE Ratio (ttm) | -1.87 |
| Forward PE | -2.73 |
| Analyst | Hold |
| Ask | 4.23 |
| Volume | 50,664 |
| Avg. Volume (20D) | 80,803 |
| Open | 3.59 |
| Previous Close | 3.45 |
| Day's Range | 3.59 - 3.93 |
| 52-Week Range | 2.55 - 7.21 |
| Beta | 1.63 |
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2020
Employees 24
Stock Exchange NASDAQ
Ticker Symbol LTRN
Website https://www.lanternpharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for LTRN stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 592.52% from the latest price.
Stock Forecasts4 months ago
+4.27%
Lantern Pharma shares are trading higher after the...
Unlock content with
Pro Subscription
4 months ago
+0.95%
Lantern Pharma shares are trading higher after the company announced LP-184 received its second fast-track designation status from the FDA for the treatment of triple-negative breast cancer.
